There is no clinically validated human dose you can look up here, because for this compound one does not exist in the way regulated drugs have. We report what research and regulators actually say, and nothing more.
What it is
Tirzepatide activates two incretin receptors at once, GIP and GLP-1, which in head-to-head trials has produced greater weight loss than single-receptor GLP-1 drugs. Like semaglutide, it is a fully approved prescription medication.
The evidence, stated plainly
Backed by the SURMOUNT (obesity) and SURPASS (diabetes) randomized trial programs. Approved for type 2 diabetes (2022), chronic weight management (2023), and moderate-to-severe obstructive sleep apnea with obesity (2024). Strong, current human evidence.
Approved by the FDA; a real label and dosing exist. We label evidence by its strongest honest tier, never by a vendor’s enthusiasm.
Half-life & timing
Roughly a 5-day half-life supports once-weekly dosing. Its dual GIP/GLP-1 mechanism is the leading explanation for its edge over semaglutide in comparative trials.
Regulatory status
FDA-approved, prescription-only, with an official titration schedule on the label. As with all approved drugs here, the dose is set and adjusted by a prescriber, not by a calculator.
Storage & handling
Refrigerate commercial product at 2 to 8 C; follow the specific label for in-use conditions.
Whatever dose a protocol or provider gave you, converting it to syringe units is where errors turn into 10× mistakes. Our calculator does only that conversion — it never invents the dose.
Open the reconstitution calculatorThe honest bottom line
Tirzepatide, like semaglutide, is an approved, trial-backed, prescriber-managed medicine. If it is on your radar, the right next step is a licensed clinician, not an unregulated source.
Sources
- FDA approval history: Mounjaro 2022, Zepbound 2023, OSA 2024.
- SURMOUNT and SURPASS randomized controlled trial programs.
- Comparative GLP-1 vs GIP/GLP-1 trial analyses.
Sourcing reflects literature available at publication and may change. See How We Rate Evidence.